PortfoliosLab logoPortfoliosLab logo
CABA vs. OLMA
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

CABA vs. OLMA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Cabaletta Bio, Inc. (CABA) and Olema Pharmaceuticals, Inc. (OLMA). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

CABA vs. OLMA - Yearly Performance Comparison


2026 (YTD)202520242023202220212020
CABA
Cabaletta Bio, Inc.
22.83%-3.52%-90.00%145.41%144.06%-69.63%-7.07%
OLMA
Olema Pharmaceuticals, Inc.
-40.36%328.82%-58.45%472.65%-73.82%-80.53%-1.88%

Fundamentals

EPS

CABA:

-$3.07

OLMA:

-$1.75

Total Revenue (TTM)

CABA:

$0.00

OLMA:

$0.00

Gross Profit (TTM)

CABA:

$0.00

OLMA:

$0.00

EBITDA (TTM)

CABA:

-$172.24M

OLMA:

-$161.30M

Returns By Period

In the year-to-date period, CABA achieves a 22.83% return, which is significantly higher than OLMA's -40.36% return.


CABA

1D
8.91%
1M
-18.98%
YTD
22.83%
6M
14.96%
1Y
94.22%
3Y*
-31.23%
5Y*
-25.51%
10Y*

OLMA

1D
11.10%
1M
-38.39%
YTD
-40.36%
6M
52.30%
1Y
296.54%
3Y*
62.57%
5Y*
-15.39%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

CABA vs. OLMA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CABA
CABA Risk / Return Rank: 7373
Overall Rank
CABA Sharpe Ratio Rank: 7070
Sharpe Ratio Rank
CABA Sortino Ratio Rank: 8080
Sortino Ratio Rank
CABA Omega Ratio Rank: 7575
Omega Ratio Rank
CABA Calmar Ratio Rank: 7272
Calmar Ratio Rank
CABA Martin Ratio Rank: 6666
Martin Ratio Rank

OLMA
OLMA Risk / Return Rank: 9393
Overall Rank
OLMA Sharpe Ratio Rank: 8989
Sharpe Ratio Rank
OLMA Sortino Ratio Rank: 9797
Sortino Ratio Rank
OLMA Omega Ratio Rank: 9696
Omega Ratio Rank
OLMA Calmar Ratio Rank: 9191
Calmar Ratio Rank
OLMA Martin Ratio Rank: 9090
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CABA vs. OLMA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Cabaletta Bio, Inc. (CABA) and Olema Pharmaceuticals, Inc. (OLMA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


CABAOLMADifference

Sharpe ratio

Return per unit of total volatility

0.82

1.84

-1.02

Sortino ratio

Return per unit of downside risk

2.05

4.00

-1.96

Omega ratio

Gain probability vs. loss probability

1.24

1.53

-0.29

Calmar ratio

Return relative to maximum drawdown

1.59

4.20

-2.62

Martin ratio

Return relative to average drawdown

2.77

11.00

-8.23

CABA vs. OLMA - Sharpe Ratio Comparison

The current CABA Sharpe Ratio is 0.82, which is lower than the OLMA Sharpe Ratio of 1.84. The chart below compares the historical Sharpe Ratios of CABA and OLMA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading graphics...

Sharpe Ratios by Period


CABAOLMADifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.82

1.84

-1.02

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.23

-0.14

-0.08

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.17

-0.19

+0.02

Correlation

The correlation between CABA and OLMA is 0.28, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Dividends

CABA vs. OLMA - Dividend Comparison

Neither CABA nor OLMA has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

CABA vs. OLMA - Drawdown Comparison

The maximum CABA drawdown since its inception was -96.63%, roughly equal to the maximum OLMA drawdown of -96.26%. Use the drawdown chart below to compare losses from any high point for CABA and OLMA.


Loading graphics...

Drawdown Indicators


CABAOLMADifference

Max Drawdown

Largest peak-to-trough decline

-96.63%

-96.26%

-0.37%

Max Drawdown (1Y)

Largest decline over 1 year

-46.37%

-62.55%

+16.18%

Max Drawdown (5Y)

Largest decline over 5 years

-95.90%

-94.36%

-1.54%

Current Drawdown

Current decline from peak

-89.40%

-72.64%

-16.76%

Average Drawdown

Average peak-to-trough decline

-58.92%

-75.04%

+16.12%

Ulcer Index

Depth and duration of drawdowns from previous peaks

26.53%

23.88%

+2.65%

Volatility

CABA vs. OLMA - Volatility Comparison

The current volatility for Cabaletta Bio, Inc. (CABA) is 20.56%, while Olema Pharmaceuticals, Inc. (OLMA) has a volatility of 37.35%. This indicates that CABA experiences smaller price fluctuations and is considered to be less risky than OLMA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading graphics...

Volatility by Period


CABAOLMADifference

Volatility (1M)

Calculated over the trailing 1-month period

20.56%

37.35%

-16.79%

Volatility (6M)

Calculated over the trailing 6-month period

78.26%

106.07%

-27.81%

Volatility (1Y)

Calculated over the trailing 1-year period

115.96%

162.85%

-46.89%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

112.81%

108.49%

+4.32%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

110.00%

107.61%

+2.39%

Financials

CABA vs. OLMA - Financials Comparison

This section allows you to compare key financial metrics between Cabaletta Bio, Inc. and Olema Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober00
(CABA) Total Revenue
(OLMA) Total Revenue
Values in USD except per share items